Reactive Oxygen Species Mediate the Suppression of Arterial Smooth Muscle T-type Ca$^{2+}$ Channels by Angiotensin II

Ahmed M. Hashad$^1$, Maria Sancho$^2$, Suzanne E. Brett$^2$ & Donald G. Welsh$^{1,2}$

Vascular T-type Ca$^{2+}$ channels (Ca$^\text{V}_3.1$ and Ca$^\text{V}_3.2$) play a key role in arterial tone development. This study investigated whether this conductance is a regulatory target of angiotensin II (Ang II), a vasoactive peptide that circulates and which is locally produced within the arterial wall. Patch clamp electrophysiology performed on rat cerebral arterial smooth muscle cells reveals that Ang II (100 nM) inhibited T-type currents through AT$_1$ receptor activation. Blocking protein kinase C failed to eliminate channel suppression, a finding consistent with unique signaling proteins enabling this response. In this regard, inhibiting NADPH oxidase (Nox) with apocynin or ML171 (Nox1 selective) abolished channel suppression highlighting a role for reactive oxygen species (ROS). In the presence of Ni$^{2+}$ (50 µM), Ang II failed to modulate the residual T-type current, an observation consistent with this peptide targeting Ca$^\text{V}_3.2$. Selective channel suppression by Ang II impaired the ability of Ca$^\text{V}_3.2$ to alter spontaneous transient outward currents or vessel diameter. Proximity ligation assay confirmed Nox1 colocalization with Ca$^\text{V}_3.2$. In closing, Ang II targets Ca$^\text{V}_3.2$ channels via a signaling pathway involving Nox1 and the generation of ROS. This unique regulatory mechanism alters BK$_\text{Ca}$ mediated feedback giving rise to a “constrictive” phenotype often observed with cerebrovascular disease.
Whole cell patch clamp recordings confirmed targeting of T-type Ca\(^{2+}\) channels by Ang II, a vasoconstrictive peptide present in cerebral circulation\(^{22}\). Ang II (100 nM) decreased peak inward Ba\(^{2+}\) current in a time-dependent manner (−1.4 ± 0.1 pA/pF to −1.2 ± 0.05 and 0.9 ± 0.05 pA/pF at 5 and 10 min, respectively) (Fig. 1). Additionally, Ang II drove a rightward shift trend in the voltage dependence of steady state activation (V\(_{50}\) activation, from −23.1 ± 1.7 mV to −15 ± −1.2 mV) but not steady state inactivation (V\(_{50}\) inactivation, from −42.1 ± 0.9 mV to −41 ± −0.9 mV). The ability of Ang II to suppress T-type activity was mediated via AT\(_1\) receptors as preincubation with 1 µM Losartan abolished all inhibitory effects (−1.47 ± 0.08 pA/pF vs −1.44 ± 0.08 pA/pF). Losartan alone had no effect on peak inward current or voltage dependence of activation/inactivation. Note, Ba\(^{2+}\) was the preferred charge carrier, as its elevated concentration promotes current flow without facilitating isolated smooth muscle cell contraction\(^{12}\).

**Results**

Whole cell patch clamp recordings confirmed targeting of T-type Ca\(^{2+}\) channels by Ang II, a vasoconstrictive peptide present in cerebral circulation\(^{22}\). Ang II (100 nM) decreased peak inward Ba\(^{2+}\) current in a time-dependent manner (−1.4 ± 0.1 pA/pF to −1.2 ± 0.05 and 0.9 ± 0.05 pA/pF at 5 and 10 min, respectively) (Fig. 1). Additionally, Ang II drove a rightward shift trend in the voltage dependence of steady state activation (V\(_{50}\) activation, from −23.1 ± 1.7 mV to −15 ± −1.2 mV) but not steady state inactivation (V\(_{50}\) inactivation, from −42.1 ± 0.9 mV to −41 ± −0.9 mV). The ability of Ang II to suppress T-type activity was mediated via AT\(_1\) receptors as preincubation with 1 µM Losartan abolished all inhibitory effects (−1.47 ± 0.08 pA/pF vs −1.44 ± 0.08 pA/pF). Losartan alone had no effect on peak inward current or voltage dependence of activation/inactivation. Note, Ba\(^{2+}\) was the preferred charge carrier, as its elevated concentration promotes current flow without facilitating isolated smooth muscle cell contraction\(^{12}\).

AT\(_1\) receptors are coupled to the classic Gq pathway which mobilizes phospholipase C, fostering diacylglycerol production and the activation of PKC\(^{17}\). Figure 2 demonstrates the conventional PKC blocker Go 6976 (100 nM) had no measurable effect on basal Ba\(^{2+}\) current or the ability of Ang II to suppress Ca\(_{\text{V}3.2}\) channels (from −1.524 ± 0.0559 pA/pF to 1.0914 ± 0.0442 pA/pF). Similar results were obtained using the broad-spectrum PKC inhibitor GF 109203 x (100 nM) (from −1.46 ± 0.06 pA/pF to −0.98 ± 0.033 pA/pF (Fig. 2). Neither blockers were associated with significant change in the voltage dependence of steady state activation/inactivation (Supplementary Figure I) We subsequently addressed the involvement of Nox, a ROS generating enzyme recently

![Figure 1](image1.png)

**Figure 1.** Angiotensin II inhibits T-type Ca\(^{2+}\) channels via the AT\(_1\) receptor in cerebral arterial smooth muscle cells. (A and B) Representative traces, averaged I-V plots, and voltage dependence of activation and steady state inactivation of whole cell T-type current prior to and following Ang II application (100 nM) (n = 8). (C and D) Representative trace and average I-V plot of the T-type current in cells treated with losartan (1 µM) and then Ang II (n = 8). (E) Peak T-type current (pA/pF) at 5 min intervals under control condition and following treatment with losartan ± Ang II (n = 8). All recordings were performed in the presence of 200 nM nifedipine and using Ba\(^{2+}\) as a charge carrier. *Denotes significant difference compared to control (*P < 0.05, paired t test).
tied to the AT1 receptor in the resistance vasculature. Apocynin (50 µM), a general Nox inhibitor, had little impact on basal currents or kinetics (Fig. 3). It did, however, abolish Ang II suppression ($-1.54 \pm 0.08$ pA/pF compared to $-1.58 \pm 0.061$ pA/pF), highlighting a role for ROS generation. While vascular smooth muscle cells express several Nox isoforms, subtype 1 has been previously implicated in mediating Ang II effects. Consistent with this perspective, selective inhibition of Nox 1 (ML171, 1 µM) eliminated Ang II suppression of the inward T-type current ($-1.7 \pm 0.07$ pA/pF versus $-1.75 \pm 0.066$ pA/pF) (Fig. 3). Similar to apocynin, ML171 had little effect on the basal current or the voltage dependence of steady state activation/inactivation (Supplementary Figure II).

Figure 2. Protein Kinase C (PKC) is not involved in angiotensin II-mediated inhibition of T-type Ca$^{2+}$ channels. (A) Representative trace, and averaged I-V plots of whole cell T-type current, prior to and after the application of Go 6976 (conventional PKC inhibitor, 100 nM) (n = 8). (B) Representative trace and average I-V plot highlighting the inability of Go 6976 to abolish Ang II (100 nM) mediated inhibition of the T-type current (n = 8). (C) Representative trace, averaged I-V plots of the whole cell T-type current, prior to and following the application of GF 109203X (non-selective PKC inhibitor, 100 nM) (n = 9). (D) Representative trace and average I-V plot highlighting the inability of GF 109203X to abolish Ang II (100 nM) mediated inhibition of the T-type current (n = 8). (E) Peak T-type current (pA/pF) at 5 min intervals under control condition (n = 8) and in cells treated with either Go 6976 or GF 109203X ± Ang II (100 nM) (n = 8–9). *Denotes significant difference compared to control (*P < 0.05, paired t test).
The T-type current in cerebral arterial smooth muscle reflects the composite activity of CaV3.1 and CaV3.2 channels. These two individual currents can be differentiated from one another by applying low micromolar Ni^{2+}, a divalent cation that selectively blocks CaV3.2. Figure 4 demonstrates that when Ni^{2+} is placed in the bath, Ang II is unable to suppress the remaining current, representative of CaV3.1 channels. Likewise, Ni^{2+} failed to augment T-current suppression in cells pretreated with Ang II compared to the effect of the vasoactive peptide alone (57.6 ± 5.84% versus 55.7 ± 6.25%, respectively). Selective targeting of CaV3.2 was further confirmed by monitoring STOC production and noting the inability of Ni^{2+} to inhibit STOC frequency in isolated cells pretreated with Ang II (100 nM) to inhibit the T-type current in cells incubated with ML171 (n = 7). Functional data aligned with Figure 3.

Figure 3. NADPH oxidase (Nox) inhibition abolishes angiotensin II suppression of the T-type Ca^{2+} current. (A) Representative trace, and averaged I-V plots of the whole cell T-type current, prior to and following the application of apocynin (non-selective Nox inhibitor, 50 µM) (n = 7). (B) Representative trace and averaged I-V plot highlighting the inability of Ang II (100 nM) to inhibit the T-type current in cells incubated with apocynin (n = 8). (C) Representative trace, and averaged I-V plots of the whole cell T-type current, prior to and following the application of ML171 (selective Nox 1 inhibitor, 1 µM) (n = 7). (D) Representative trace and average I-V plot highlighting the inability of Ang II (100nM) to inhibit the T-type current in cells incubated with ML171 (n = 7). (E) Peak T-type current (pA/pF) at 5 min time intervals under control condition (n = 8) or in cells treated with either apocynin or ML171 ± Ang II (n = 7–8). *Denotes significant difference compared to control (*P < 0.05, paired t test).
electrophysiological observations in that Ni2+ application failed to increase myogenic tone (4% change) in arteries pretreated with Ang II compared to the 25% rise under standard conditions. Intriguingly, the Ni2+ mediated increase in myogenic tone was restored in arteries that were pretreated with apocynin, a finding consistent with ROS modulating CaV3.2 (Fig. 5). Similar results were obtained with the Nox1 inhibitor ML171 (Supplementary Figure III). Pretreating arteries with the Ni2+ did not alter their responsiveness to Ang II (Supplementary Figure IV). Such observations structurally imply that the ROS generating enzyme Nox1 colocalizes with CaV3.2. This was confirmed with the proximity ligation assay (Fig. 6); punctate red fluorescent product was observed in cells treated with both primary antibodies (anti CaV3.2 and anti Nox1) in keeping with proteins residing within 40 nm of one another. Fluorescent product was absent in control experiments where one or both primary antibodies were omitted. Further control experiments reveal no similar co-localization pattern between Nox1 and CaV3.1, a secondary T-type Ca2+ channel expressed in cerebral arteries (Fig. 6).

**Discussion**

This study examined whether and by what mechanism Ang II modulates T-type Ca2+ channels in cerebral arterial smooth muscle cells. This constrictor peptide was initially observed to suppress T-type channels via activation of AT1 receptors and a signaling pathway independent of PKC. The inhibition of Nox, a unique signaling protein involved in local ROS generation, abolished Ang II suppression. Further experiments revealed that Ang II specifically targets CaV3.2 channels via Nox1, two proteins that localize within 40 nm of one another. Functionally, Ang II mediated T-channel suppression will impair STOC production at physiological voltages, reducing negative feedback and facilitating arterial constriction. This study is the first in vascular tissue to consider T-type Ca2+ channels as a regulatory target of Ang II and downstream Nox signaling in the genesis of arterial constriction (Fig. 7).
Background. Cerebral arterial tone is actively controlled by vasoactive stimuli present in the systemic circulation or locally produced within tissue\(^1,2\). Dynamic tuning is intimately tied to membrane potential and the gating of L-type Ca\(^{2+}\) channels which sets cytosolic [Ca\(^{2+}\)] and the activity of myosin light chain kinase\(^26,27\). In addition to L-type channels, two T-type channels (Ca\(V\) 3.1 and Ca\(V\) 3.2) are expressed in cerebral arterial smooth muscle, each of which subtly contributes to tone development in a mechanistically unique manner\(^6,28\). Of particular note is Ca\(V\) 3.2, a channel whose opening paradoxically limits arterial constriction by discretely triggering Ca\(^{2+}\) release from ryanodine receptors (RyR) localized to the sarcoplasmic reticulum\(^8\). These transient events activate BK Ca channels, driving STOC production, hyperpolarizing events which attenuate arterial constriction\(^29\). In considering the close and evolving relationship between Ca\(V\) 3.2 and STOC production, mechanistic questions logically arise as to the dynamic regulation of this feedback cascade. Vasoconstrictors for example, including those that circulate systemically or produced locally in the arterial wall (Ang II) suppress this cascade and facilitate arterial tone generation\(^19,30\). This suppression is often attributed to a direct BK Ca suppression with little consideration that the upstream initiators of Ca\(^{2+}\) sparks may themselves be the target of inhibition\(^11,31\). It is this issue that will be addressed in the current manuscript.

Initial Experimentation. Work began by examining the effect of Ang II on Ca\(V\) 3.x channels expressed in cerebral arterial smooth muscle cells\(^6\). Patch clamp electrophysiology revealed that this vasoactive peptide suppressed the T-type current in a time dependent manner, and initiated a rightward shift trend in the voltage dependency of activation (Fig. 1). The contractile effects of Ang II are typically mediated through AT\(_1\) and AT\(_2\) receptors, with the former expressed in smooth muscle and tied to constriction, and the latter present in endothelium and intimately tied to nitric oxide production\(^32,33\). Consistent with the involvement of AT\(_1\) receptors, Losartan, a known anti-hypertensive agent, abolished Ang II suppression of the T-type current. As AT\(_1\) receptors are G\(_q\) coupled, it is logical to deduce that Ang II suppression is linked to phospholipase C-\(\beta\) and the mobilization of PKC, a phosphoprotein known to target multiple ion channels\(^17,34,35\). Surprisingly, both conventional and broad spectrum PKC inhibitor (Go 6976 and GF 109203X, respectively), previously shown to interfere with phorbol ester induced constriction, failed to abolish T-type current suppression (Fig. 2)\(^36\). These observations suggest that AT\(_1\) receptor signaling is diverse in cerebral arterial smooth muscle and that other downstream effectors are uniquely involved in targeting the T-type current.

Involvement of Reactive Oxygen Species. Ang II application in the cerebral circulation elevates ROS production through the stimulation of the AT\(_1\) receptor\(^33,37\). While several ROS generating mechanisms are present in this vascular bed, Nox is of particular importance due to its presumed coupling with the AT\(_1\) receptor\(^15,38\).

Figure 5. Angiotensin II abolishes Ni\(^{2+}\)’s ability to inhibit STOCs and augment myogenic tone. (A) Representative traces and summary data showing Ni\(^{2+}\) (50 µM)-induced inhibition of STOC frequency in absence (n = 6) and presence (n = 6) of Ang II (100 nM). Perforated patch clamp electrophysiology was used to measure STOCs in cerebral arterial smooth muscle cells held at −40 mV. (B) Representative trace and summary data comparing the effect of Ni\(^{2+}\) on myogenic tone (60 mmHg) in absence (n = 5) and presence (n = 5) of Ang II. Ni\(^{2+}\) failed to alter arterial tone in vessels pretreated with Ang II, a phenomenon reversed with Nox inhibition with apocynin (50 µM) (n = 5). *Denotes significant difference (*P < 0.05, paired t test).
and its ability to regulate Ca\(^{2+}\) conductances including L-type Ca\(^{2+}\) channels\(^{30}\). Consistent with ROS generation impacting a broader range of Ca\(^{2+}\) permeable pores, pretreating cells with the pan selective Nox inhibitor apocynin abolished the suppressive effects of Ang II on T-type channels (Fig. 3). While impactful on Ang II mediated

Figure 6. Proximity ligation assay of Ca\(_{\text{v}}\)3.2 and Nox1 in cerebral arterial smooth muscle cells. Representative images revealing the close proximity (<40 nM) of Ca\(_{\text{v}}\)3.2 with Nox1 as demonstrated by the presence of red fluorescent products; nuclei were labelled with DAPI (blue). A similar localization pattern between Nox1 and other vascular T-type channels (Ca\(_{\text{v}}\)3.1) could not be detected. Assay controls were performed with one or both primary antibodies removed. Each experiment was performed on cells for 4 different animals; photomicrographs are representative 10–20 smooth muscle cells per group.
Figure 7. Schematic diagram highlighting the mechanism of Ang II suppression of CaV3.2 channels and its functional impact on the BKCa mediated feedback in cerebral arteries.

effects, apocynin had no measurable impact on peak inward current or activation/inactivation kinetics under basal conditions. Of the seven known Nox isoforms, three have been identified at the molecular level in cerebral arteries, two of which (Nox1 and Nox4) are expressed in vascular smooth muscle. Observations from knockout and transgenic mice suggest that Nox1 is a key downstream target of the AT1 receptor and important to mediating ROS generation in vasculature. In alignment with this observation, the Nox1 selective inhibitor, ML171 attenuated the ability of Ang II to suppress the T-type current in cerebral arterial smooth muscle (Fig. 3).

The T type current in vascular smooth muscle is representative of both CaV3.1 and CaV3.2 and in theory Ang II could be targeting one or both of the channel subtypes. The two CaV3.x subtypes can be differentiated from one another using Ni2+, a divalent cation when applied at low micromolar concentrations will selectively blocks CaV3.2. In the presence of 50 µM Ni2+ the addition of Ang II failed to modulate the remaining T-type current, representative of CaV3.1 (Fig. 4). Ni2+ had no inhibitory effect in smooth muscle cells pretreated with Ang II and together both findings suggest that AT1 receptors and the downstream generation of ROS are selectively targeting CaV3.2 channels. While the precise mechanism of inhibition remains unclear, past work in neuronal tissue has noted that oxidation of histidine residue H191 potently inhibits CaV3.2 channels. The selective targeting of CaV3.2 has potentially important implications in regard to resident feedback loops present in cerebral arterial smooth muscle cells. In detail, CaV3.2 has been reported to trigger the cytosolic gate of RyR, initiating Ca2+ sparks that sequentially activate BKCa channels, generating a hyperpolarization that moderates arterial constriction. Ni2+ failed to reduce STOC frequency in cells, or enhance arterial tone in vessels, superfused with Ang II (Fig. 5). Intriguingly, Ni2+ mediated increases in arterial tone could be restored if vessels were pretreated with apocynin or ML171, prior to Ang II addition. This particular finding further confirms a role for ROS and to our knowledge the first to demonstrate selective modulation of CaV3.2 in the cerebral vasculature.

As ROS molecules are remarkably labile, targeted redox signaling can only occur if a defined enzyme generating system is compartmentalized in close apposition to the selected protein. We consequently presumed, given the preceding observations, that Nox1 and CaV3.2 colocalize with one another, perhaps in caveolae where both proteins have been reported to reside. One means of detecting close interaction is to employ the proximity ligation assay, a technique where two secondary antibodies with attached DNA strands bound to two distinct primary antibodies form a circular template for DNA amplification if the targeted proteins are within 40 nM of one another. Consistent with close apposition among CaV3.2 and Nox1, punctate red fluorescence label was detected on the smooth muscle cell membrane (Fig. 6). Fluorescence labeling was absent in experiments where one or both primary antibodies were removed from the biochemical process. This localization pattern was unique to CaV3.2 and didn’t extend to CaV3.1 (Fig. 6), a result which highlights regulatory distinction among T-type Ca2+ channels.

Broader Implications. Tone development is intimately tied to changes in arterial membrane potential and the subsequent rise of intracellular [Ca2+] via L-type Ca2+ channels. Membrane potential is in turn driven by a range of conductances, several of which are assigned the role of feeding back negatively upon depolarization, to prevent vessels from overly constricting. As noted above, BKCa is a key feedback element and a channel whose activity is regulated indirectly by CaV3.2 and a discrete influx of Ca2+ that triggers the cytosolic gate of RyR8. It is clear that Ang II suppresses CaV3.2 activity and with it the resultant feedback loop, an observation with implications to vascular disease. High renin models of hypertension are typically associated with both an increase in arterial tone and a rise in ROS production. It is intriguing to consider whether ROS generation partially drives the rise in tone through an axis sequentially entailing the AT1 receptor, Nox1, CaV3.2, Ca2+ sparks and the transiently opening BKCa. In considering this potential mechanism, it’s important to acknowledge that CaV3.2 is not the sole conductance that triggers the opening of RyR and the generation of Ca2+ sparks. There is a complementary role for L-type Ca2+ channels and the Na+/Ca2+ exchanger particularly at depolarized potentials whose resident activity may also be impacted by the hypertensive state.

Summary. Findings in this study support the emerging view that T-type Ca2+ channels are a rich regulatory target for vasoactive stimuli. In addition to being modulated by dilatory protein kinases, the current study shows...
that particular Ca_{v}3.x channels are targeted by vasoconstrictors and their associated receptors/signaling pathways. This includes Nox mediated generation of ROS via the AT_{1} receptor, a process that selectively suppresses Ca_{v}3.2 and along with it BK_{ca} mediated feedback in the cerebral vasculature (Fig. 7). These findings elucidate a new mechanism of arterial tone regulation, one that could contribute to the excessive constricted state observed with advancing vascular disease.

**Materials and Methods**

**Animal procedures.** Animal procedures and methods were approved by the Animal Care and Use Committees at the University of Calgary and the University of Ontario and in accordance with the Canadian Institute of Health Research (CIHR) guidelines. Female Sprague–Dawley rats (10–12 weeks of age) were euthanized by CO_{2} asphyxiation. The brain was carefully removed and placed in cold phosphate-buffered saline (PBS, pH 7.4) solution containing (in mM): 138 NaCl, 3 KCl, 10 Na_{2}HPO_{4}, 2 NaH_{2}PO_{4}, 5 glucose, 0.1 CaCl_{2}, and 0.1 MgSO_{4}. Middle and posterior cerebral arteries were isolated and cut into 2–3 mm segments.

**Isolation of Cerebral Arterial Smooth Muscle Cells.** Middle and posterior cerebral arteries were enzymatically digested to liberate smooth muscle cells. Briefly, arterial segments were placed in an isolation medium (37 °C, 10 minutes) containing (in mM): 60 NaCl, 80 Na-glutamate, 5 KCl, 2 MgCl_{2}, 10 glucose and 10 HEPES with 1 mg/ml bovine serum albumin (pH 7.4). Vessels were then exposed to a two-step digestion process that involved: 1) 14 minutes incubation in isolation medium (37 °C) containing 0.5 mg/ml papain and 1.5 mg/ml dithioerythritol; and 2) 10 minutes incubation in isolation medium containing 100 μM Ca^{2+}, 0.7 mg/ml type F collagenase and 0.4 mg/ml type H collagenase. Following incubation, tissues were washed repeatedly with ice-cold isolation medium and triturated with a fire-polished pipette. Liberated cells were stored in ice-cold isolation medium for use the same day within ~5 hours.

**Electrophysiological Recordings.** Whole cell currents were measured in isolated cerebral arterial smooth muscle cells. Current was recorded using an Axopatch 200B patch-clamp amplifier (Molecular Devices, Sunnyvale, CA), filtered at 1 kHz, digitized at 5 kHz, and were stored on a computer for offline analysis with Clampfit 10.3 software (Molecular Devices, Sunnyvale, CA). Whole-cell capacitance averaged 12–18 pF and was assessed by brief application of 60 mM KCl. Following equilibration, intravascular pressure was elevated from 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dilation. Arteries were equilibrated at 15 mmHg and contractile responsiveness to the loss of bradykinin-induced dil.
Proximity Ligation Assay (PLA). The Duolink in situ PLA detection kit was employed using freshly isolated smooth muscle cells. Briefly, cells were first fixed in PBS containing 4% paraformaldehyde (15 min), and then incubated with PBS containing 0.2% tween (15 min) for permeabilization. Cells were washed with PBS, blocked by Duolink blocking solution (1 hr), and incubated overnight with primary antibodies (mouse anti-CaV3.2 or mouse anti CaV3.1 and rabbit anti Nox1) in Duolink antibody diluent solution at 4 °C. Control experiments employed no primary antibody or one primary antibody. Cells were then washed with Duolink washing solution, and labelled with Duolink PLA PLUS and MINUS probes for 1 hr (37 °C). The secondary antibodies of PLA PLUS and MINUS probes are attached to synthetic oligonucleotides that hybridize if present in close proximity (<40 nm). The hybridized oligonucleotides are then ligated and subjected to amplification. The amplified products extending from the oligonucleotide arm of the PLA probe were detected using far red fluorescent fluorophore-tagged, complementary oligonucleotide sequences and Leica TCS SP8 confocal microscope.

Chemicals and Statistical Analysis. GF 109203X was purchased from Calbiochem. Ang II, losartan, Go 6976, apocynin, and ML-171 were obtained from Tocris. Primary antibodies against CaV3.2, CaV3.1 and Nox1 were purchased from Novus Biologicals. Duolink PLA detection kit and all other chemicals were obtained from Sigma Aldrich. Data are expressed as means ± S.E., and n indicates the number of cells or cultures or animals. Paired t-test was performed to compare the effects of a given condition/treatment on whole cell current or arterial diameter. P values ≤ 0.05 were considered statistically significant.

Data Availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author in a reasonable request.

References

1. Furchgott, R. F. & Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288, 373–376 (1980).
2. Pilola, J. A. et al. Local potassium signaling couples neuronal activity to vasodilation in the brain. Nat. Neurosci. 9, 1397–1403 (2006).
3. Moosmang, S. et al. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J. 22, 6027–6034 (2003).
4. Rubart, M., Patlak, J. B. & Nelson, M. T. Ca2+ currents in cerebral artery smooth muscle cells of rat at physiological Ca2+ concentrations. J. Gen. Physiol. 107, 459–472 (1996).
5. Keef, K. D., Hume, J. R. & Zhong, J. Regulation of cardiac and smooth muscle Ca2+ channels (CaV1.2a,b) by protein kinases. Am. J. Physiol Cell Physiol. 281, C1743–C1756 (2001).
6. Abd El-Rahman, R. R. et al. Identification of L- and T-type Ca2+ channels in rat cerebral arteries: role in myogenic tone development. Am. J. Physiol Heart Circ. Physiol. 304, H58–H71 (2013).
7. Kuo, I. Y., Ellis, A., Seymour, V. A., Sandow, S. L. & Hill, C. E. Dihydropyridine-insensitive calcium currents contribute to function of small cerebral arteries. J. Cereb. Blood Flow Metab. 30, 1226–1239 (2010).
8. Harraz, O. F. et al. CaV3.2 channels and the induction of negative feedback in cerebral arteries. Circ. Res. 115, 650–661 (2014).
9. Nelson, M. T. et al. Relaxation of arterial smooth muscle by calcium sparks. Science. 270, 633–637 (1995).
10. Harraz, O. F. et al. CaV1.2/CaV3.x channels mediate divergent vasomotor responses in human cerebral arteries. J. Gen. Physiol. 145, 405–418 (2015).
11. Nelson, M. T. & Quayle, J. M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am. J. Physiol. 268, C799–C822 (1995).
12. Harraz, O. F. & Welsh, D. G. Protein kinase A regulation of T-type Ca2+ channels in rat cerebral arterial smooth muscle. J. Cell Sci. 126, 2944–2954 (2013).
13. Harraz, O. F., Brett, S. E. & Welsh, D. G. Nitric oxide suppresses vascular voltage-gated T-type Ca2+ channels through cGMP/PKG signaling. Am. J. Physiol Heart Circ. Physiol. 306, H279–H285 (2014).
14. Nguyen Dinh, C. A. & Touyz,R.M. A new look at the renin-angiotensin system—focusing on the vascular system. Peptides. 32, 2141–2150 (2011).
15. De Silva, T. M. & Faraci, F. M. Effects of angiotensin II on the cerebral circulation: role of oxidative stress. Front Physiol. 3:484, https://doi.org/10.3389/fphys.2012.00484. eCollection; 2012, 484 (2012).
16. Capone, C. et al. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am. J. Physiol Heart Circ. Physiol. 300, H397–H407 (2011).
17. Higuchi, S. et al. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin. Sci. (Lond). 112, 417–428 (2007).
18. Touyz, R. M. & Schiffrin, E. L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. 52, 639–672 (2000).
19. Am. J. Physiol Cell Physiol. 279, C1528–C1539 (2000).
20. Hashad, A. M. et al. Interplay among distinct Ca2+ conductances drives Ca2+ sparks/spontaneous transient outward currents in rat cerebral arteries. J. Physiol. 595, 1111–1126 (2017).
21. Young, C. N. & Davison, R. L. Angiotensin II, the Brain, and Hypertension: An Update. Hypertension. 66, 920–926 (2015).
22. Matsuno, K. et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation. 112, 2677–2685 (2005).
23. Lassegue, B. et al. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide production and redox-sensitive signaling pathways. Circ. Res. 88, 888–894 (2001).
24. Harraz, O. F. et al. Genetic ablation of CaV3.2 channels enhances the arterial myogenic response by modulating the RyR/BKCa axis. Arterioscler. Thromb. Vasc. Biol. 35, 1843–1851 (2015).
25. Bonev, A. D., Jaggar, J. H., Rubart, M. & Nelson, M. T. Activators of protein kinase C decrease Ca2+ spark frequency in smooth muscle cells from cerebral arteries. Am. J. Physiol. 273, C2090–C2095 (1997).
26. Jaggar, J. H. & Nelson, M. T. Differential regulation of Ca2+ sparks and Ca2+ waves by UTP in rat cerebral artery smooth muscle cells. Am. J. Physiol Cell Physiol. 279, C1528–C1539 (2000).
27. Cole, W. C. & Welsh, D. G. Role of myosin light chain kinase and myosin light chain phosphatase in the resistance arterial myogenic response to intravascular pressure. Arch. Biochem. Biophys. 510, 160–173 (2011).
28. Navarro-Gonzalez, M. F., Grayson, T. H., Meaney, K. R., Cribris, L. L. & Hill, C. E. Non-L-type voltage-dependent calcium channels control vascular tone of the rat basilar artery. Clin. Exp. Pharmacol. Physiol. 36, 55–66 (2009).

www.nature.com/scientificreports/
29. Knot, H. J., Staden, N. B. & Nelson, M. T. Ryanodine receptors regulate arterial diameter and wall [Ca\textsuperscript{2+}] in cerebral arteries of rat via Ca\textsuperscript{2+}-dependent K\textsuperscript{+} channels. *J. Physiol.* **508**, 211–221 (1998).
30. Toro, L. et al. MaxiK channel and cell signalling. *Pflugers Arch.* **466**, 875–886 (2014).
31. Zhang, Z. et al. The angiotensin II type 1 receptor (AT1R) closely interacts with large conductance voltage- and Ca\textsuperscript{2+}-activated K\textsuperscript{+} (BK) channels and inhibits their activity independent of G-protein activation. *J. Biol. Chem.* **289**, 25678–25689 (2014).
32. Mehta, P. K. & Griendling, K. K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *Am. J. Physiol Cell Physiol.* **292**, C82–C97 (2007).
33. Vincent, J. M. et al. Constrictor and dilator effects of angiotensin II on cerebral arterioles. *Stroke.* **36**, 2691–2695 (2005).
34. Earley, S., Straub, S. V. & Brayden, J. E. Protein kinase C regulates vascular myogenic tone through activation of TRPM4. *Am. J. Physiol Heart Circ. Physiol.* **292**, H2613–H2622 (2007).
35. Navedo, M. F., Amberg, G. C., Nieves, M., Molkentin, J. D. & Santana, L. F. Mechanisms underlying heterogeneous Ca\textsuperscript{2+} sparklet activity in arterial smooth muscle. *J. Gen. Physiol.* **127**, 611–622 (2006).
36. Luykenaar, K. D., Brett, S. E., Wu, B. N., Wielier, W. B. & Welsh, D. G. Pyrimidine nucleotides suppress KDR currents and depolarize rat cerebral arteries by activating Rho kinase. *Am. J. Physiol Heart Circ. Physiol.* **286**, H1088–H1100 (2004).
37. Nguyen Dinh, C. A., Montezano, A. C., Burger, D. & Touyz, R. M. Angiotensin II, NAPDH oxidase, and redox signaling in the vasculature. *Antioxid. Redox. Signal.* **19**, 1110–1120 (2013).
38. Chriisobolis, S., Bani, R., Sobey, C. G. & Faraci, F. M. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. *J. Appl. Physiol.* (1985.) **113**, 184–191 (2012).
39. Amberg, G. C., Earley, S. & Glapa, S. A. Local regulation of arterial L-type calcium channels by reactive oxygen species. *Circ. Res.* **107**, 1002–1010 (2010).
40. Drummond, G. R., Selemidis, S., Griendling, K. K. & Sobey, C. G. Combating oxidative stress in vascular disease: NAPDH oxidases as therapeutic targets. *Nat. Rev. Drug Discov.* **10**, 453–471 (2011).
41. Miller, A. A., Drummond, G. R., Mast, A. E., Schmidt, H. H. & Sobey, C. G. Effect of gender on NAPDH-oxidase activity, expression, and function in the cerebral circulation: role of estrogen. *Stroke.* **38**, 2142–2149 (2007).
42. Dikalova, A. et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. *Circulation.* **112**, 2668–2676 (2005).
43. Gavazzi, G. et al. Decreased blood pressure in NOX1-deficient mice. *FEBS Lett.* **580**, 497–504 (2006).
44. Orestes, P. et al. Free radical signalling underlies inhibition of Ca_{\text{L}2} T-type calcium channels by nitrosyde in the pain pathway. *J. Physiol.* **589**, 135–148 (2011).
45. Brandes, R. P. & Schroder, K. Differential vascular functions of Nox family NAPDH oxidases. *Curr. Opin. Lipidol.* **19**, 513–518 (2008).
46. Milewski, J. L., Clempus, R. E., Quinn, M. T., Lambeth, J. D. & Griendling, K. K. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* **24**, 677–683 (2004).
47. Cole, W. C., Plane, F. & Johnson, R. Role of Kv1 channels in control of arterial myogenic reactivity to intraluminal pressure. *Circ. Res.* **97**, e1 (2005).
48. Cox, R. H. Changes in the expression and function of arterial potassium channels during hypertension. *Vasc. Pharmacol.* **38**, 13–23 (2002).
49. Rivera, J., Sobey, C. G., Walduck, A. K. & Drummond, G. R. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. *Redox. Rep.* **15**, 50–63 (2010).
50. Sobey, C. G. Potassium channel function in vascular disease. *Arterioscler. Thromb. Vasc. Biol.* **21**, 28–38 (2001).

**Acknowledgements**

The authors would like to acknowledge the technical support of Aly Balbaa. This work is supported by an operating grant from the Canadian Institute of Health Research (FRN-106459 to DG Welsh). DG Welsh is the Rorabeck Chair in Molecular Neuroscience and Vascular Biology at the University of Western Ontario. AM Hashad is a Vanier Scholar (CIHR) and was supported by salary studentship from Alberta Innovates Health Solutions (AIHS).

**Author Contributions**

A.M.H. and D.G.W. designed the research; A.M.H., M.S. and S.E.B. performed experiments and analyzed data; A.M.H. and D.G.W. interpreted the results of experiments; A.M.H. and D.G.W. prepared figures and drafted the manuscript; A.M.H., S.E.B. and D.G.W. revised and approved the final version of the manuscript.

**Additional Information**

Supplementary information accompanies this paper at [https://doi.org/10.1038/s41598-018-21899-5.](https://doi.org/10.1038/s41598-018-21899-5)

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018